These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6362863)

  • 1. Importance of prognostic factors in cancer clinical trials.
    Simon R
    Cancer Treat Rep; 1984 Jan; 68(1):185-92. PubMed ID: 6362863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group Report.
    Miller DR; Leikin S; Albo V; Vitale L; Sather H; Coccia P; Nesbit M; Karon M; Hammond D
    Cancer Treat Rep; 1980; 64(2-3):381-92. PubMed ID: 6931631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of prognostic knowledge in the planning and analysis of randomized therapeutic trials].
    Byar D; Chastang C
    Bull Cancer; 1987; 74(2):177-84. PubMed ID: 3607300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biostatistical aspects of adjuvant therapy assay.
    Hudec M; Platz H
    Drugs Exp Clin Res; 1986; 12(1-3):73-81. PubMed ID: 3732057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the study of prognostic factors to the treatment of childhood (less than 20 years old) acute lymphoblastic leukemia.
    Jacquillat C; Weil M; Auclerc MF; Schaison G; Chastang C; Harousseau JL; Bauters F; Olive D; Griscelli C; Bonnet M; Lamagnere JP; Bernard J
    Bull Cancer; 1980; 67(4):458-69. PubMed ID: 7013865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing for cancer clinical trials: selection of prognostic factors.
    Brown BW
    Cancer Treat Rep; 1980; 64(2-3):499-502. PubMed ID: 7407790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.
    Ransohoff DF
    J Clin Epidemiol; 2007 Dec; 60(12):1205-19. PubMed ID: 17998073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in clinical cancer trials.
    Estey E
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2591-3. PubMed ID: 9815662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect.
    Kyzas PA; Denaxa-Kyza D; Ioannidis JP
    J Natl Cancer Inst; 2007 Feb; 99(3):236-43. PubMed ID: 17284718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic knowledge: interest and methods.
    Chastang C; Auquier A; Gremy F
    Bull Cancer; 1980; 67(4):430-6. PubMed ID: 7013863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell membrane differences between malignant and nonmalignant cells].
    Suschke HJ; Bender-Götze C; Brosse J; Kunze D; Rosendahl C; Walther U
    Monatsschr Kinderheilkd; 1985 Dec; 133(12):891-3. PubMed ID: 3866952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment prognostic factors and hospitalization periods in childhood acute lymphoblastic leukemia.
    Ramot B; Modan M; Meerowitz Y; Potashnick D; Kende G; Berkowicz M
    Isr J Med Sci; 1982 Apr; 18(4):447-55. PubMed ID: 6953056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
    Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
    Chau I; Norman AR; Cunningham D; Waters JS; Oates J; Ross PJ
    J Clin Oncol; 2004 Jun; 22(12):2395-403. PubMed ID: 15197201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient heterogeneity in clinical trials.
    Simon R
    Cancer Treat Rep; 1980; 64(2-3):405-10. PubMed ID: 7407777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of prognostic factors in analysis of historical control studies.
    Gehan EA; Smith TL; Buzdar AU
    Cancer Treat Rep; 1980; 64(2-3):373-9. PubMed ID: 7407774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment by drawing lots in a therapeutic trial with a balance distribution of prognostic factors: the minimization method].
    Mollié A; Hill C
    Rev Epidemiol Sante Publique; 1988; 36(2):138-43. PubMed ID: 3045921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
    Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
    Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in unknown primary cancer.
    Culine S
    Semin Oncol; 2009 Feb; 36(1):60-4. PubMed ID: 19179189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.